Sanremo, Italy

John Mcwhirter

This inventor holds 1 USPTO granted patent and 4 published patent applications and 3 EPO patents. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Mcwhirter. Retrieved from https://idiyas.com/inventor/john-mcwhirter-57oy0j93

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Mcwhirter - Innovator in Biotechnology

Introduction

John Mcwhirter is an inventor based in Sanremo IM, Italy. He is currently associated with Regeneron Pharmaceuticals, Inc. Although he does not hold any granted patents, his contributions to the field of biotechnology are noteworthy.

Latest Patent Applications

One of his significant patent applications is titled "Non-Human Animals Having a Humanized B-Cell Activating Factor Gene." This application describes non-human animals, cells, methods, and compositions for making and using the same. The focus is on non-human animals and cells that comprise a humanized B-cell activating factor gene. Additionally, it details non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus.

Conclusion

John Mcwhirter's work in biotechnology, particularly in the area of humanized B-cell activating factor genes, showcases his innovative approach to scientific research. His contributions, although not yet reflected in granted patents, hold potential for future advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…